NCT03816332: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

NCT03816332
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be kidney transplant recipients
Exclusions: Patients must not have had prior treatment with an anti-PD-1/L1/L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways; Patients with known untreated unstable central nervous system (CNS) metastases or leptomeningeal metastases – see trial for details
https://ClinicalTrials.gov/show/NCT03816332

Comments are closed.

Up ↑